Skip Navigation


Annals of Oncology Advance Access originally published online on June 6, 2005
Annals of Oncology 2005 16(7):999-1004; doi:10.1093/annonc/mdi208
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/999    most recent
mdi208v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Midgley, R.
Right arrow Articles by Kerr, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Midgley, R.
Right arrow Articles by Kerr, D.
Related Collections
Right arrow 2005 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Review

Bevacizumab—current status and future directions

Rachel Midgley* and David Kerr

Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK

* Correspondence to: Dr R. Midgley, Cancer Research UK, Churchill Hospital, Headington, Oxford, UK, OX3 7LJ. Email: rachel.midgley{at}cancer.org.uk

Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer development. Bevacizumab (a humanised monoclonal antibody against VEGF) has a reasonable safety profile and proven efficacy in a phase III trial in advanced colorectal cancer. Efficacy of Bevacizumab also looks promising in non small cell lung cancer, renal cancer and a variety of other solid tumours. Questions still surround optimal dosing and the appropriate selection of patients who are most likely to benefit. Future trials will address these questions and provide further translational insights.

Key words: angiogenesis, bevacizumab, vascular endothelial growth factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
Z. Li, T. Van Bergen, S. Van de Veire, I. Van de Vel, H. Moreau, M. Dewerchin, P. C. Maudgal, T. Zeyen, W. Spileers, L. Moons, et al.
Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery
Invest. Ophthalmol. Vis. Sci., November 1, 2009; 50(11): 5217 - 5225.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist, May 1, 2009; 14(5): 511 - 525.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
A. L. Uy, N. B. Simper, A. L. Champeaux, and R. M. Perkins
Progressive bevacizumab-associated renal thrombotic microangiopathy
NDT Plus, February 1, 2009; 2(1): 36 - 39.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
JAMA, November 19, 2008; 300(19): 2277 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H.-J. Raatschen, G. H. Simon, Y. Fu, B. Sennino, D. M. Shames, M. F. Wendland, D. M. McDonald, and R. C. Brasch
Vascular Permeability during Antiangiogenesis Treatment: MR Imaging Assay Results as Biomarker for Subsequent Tumor Growth in Rats
Radiology, May 1, 2008; 247(2): 391 - 399.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. E. Strome, E. A. Sausville, and D. Mann
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Oncologist, September 1, 2007; 12(9): 1084 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Yoon, D Schmassmann-Suhijar, M Zuber, P Konietzny, and A Schmassmann
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta
Ann. Onc., December 1, 2006; 17(12): 1851 - 1852.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms.
Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
V. R. Adams
Evolving role of antineoplastic agents in colorectal cancer
Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S4 - S11.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Hall, F. R. Westwood, and P. F. Wadsworth
Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate
Toxicol Pathol, February 1, 2006; 34(2): 131 - 147.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. Wolmark
Provocative Optimism in the Treatment of Early Stage Disease
Oncologist, October 1, 2005; 10(suppl_2): 1 - 3.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.